European Society for Medical Oncology (ESMO) 2024
ESMO recently held its 2024 conference from September 13-17, 2024 in Barcelona, Spain. Click the links below to learn about MBC-related results from this meeting.
Results for HER2+ MBC
- Practice Update: Combination treatment with or without chemotherapy led to the same overall survival and progression-free survival in HER2+, hormone receptor-positive MBC
- Breastcancer.org: Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu®) controls MBC that has spread to the brain
Results for Hormone Receptor-Positive MBC
- Gustave Roussy: The antibody-drug conjugate, patritumab deruxtecan, shows encouraging progression-free survival compared to chemotherapy for hormone receptor-positive MBC that is resistant to CDK4/6 inhibitors and one line of chemotherapy (scroll down for English)
Results for Multiple Types of MBC
- ESMO Daily Reporter: Antibody-drug conjugates continue to be promising for MBC
- ESMO Daily Reporter: New treatments that target CDK2 show promising results in hormone receptor-positive MBC and triple-negative MBC (scroll to the paragraph beginning “Finally, two early-phase trials provide further insights…”)